Headaches are one of the most common medical complaints, with up to 47% of adults experiencing them on a regular basis. While there are a variety of treatments available, some headaches remain mysterious and challenging to treat. Paroxysmal hemicrania (PH) is one such headache disorder, characterized by sudden, intense, and recurrent episodes of pain on one side of the head. Despite the fact that PH has been recognized for over 40 years, it remains a largely unexplored mystery in the field of headache treatment. This article will explore the current understanding of PH, its diagnosis, and potential treatments.
Paroxysmal hemicrania is a rare type of primary headache disorder, meaning it is not caused by an underlying medical condition. It was first described in 1976 by Dr. J.M. Sjaastad and colleagues. PH is characterized by sudden, intense, and recurrent episodes of pain on one side of the head. The pain is usually localized to the area around the eye, but can spread to the forehead, temple, and even the neck. The episodes of pain can last anywhere from a few seconds to several minutes, and can occur multiple times a day.
The diagnosis of PH is based on a combination of clinical history, physical examination, and laboratory tests. The diagnosis is made based on the presence of certain criteria, such as the presence of recurrent and unilateral attacks of severe, short-lasting pain, lasting from 5 seconds to 30 minutes. Other criteria include the presence of autonomic symptoms, such as tearing, redness, and nasal congestion, as well as the absence of any other causes of headache.
The treatment of PH is largely based on the use of medications. Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used to reduce the frequency and intensity of the attacks. Other medications such as triptans, anticonvulsants, and calcium channel blockers may also be used. In addition, certain lifestyle modifications, such as avoiding triggers, can be helpful in managing the disorder.
Despite the fact that PH has been recognized for over 40 years, research into the disorder is still in its early stages. The mechanisms underlying the disorder are still largely unknown, and there is a lack of clinical studies to evaluate the efficacy of available treatments. Furthermore, the diagnosis of PH can be difficult, as it is often misdiagnosed as a migraine or cluster headache.
Paroxysmal hemicrania is a rare and mysterious primary headache disorder, characterized by sudden, intense, and recurrent episodes of pain on one side of the head. While there are treatments available, research into the disorder is still in its early stages, and the diagnosis can be difficult. As such, PH remains a largely unexplored mystery in the field of headache treatment. With further research, it is hoped that more effective treatments can be developed to help those who suffer from this disorder.
1.
Certain surgical gestures during prostate removal linked to better sexual function recovery
2.
There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.
3.
In patients with advanced lung cancer, cemiplimab combined with chemotherapy extends life and enhances quality of life.
4.
An "exploding" field of antibody-drug conjugates is making progress against ovarian cancer.
5.
Black women have a higher risk of dying from all types of breast cancer, meta-analysis reveals
1.
Trends in Incidence, Care, and Surgery for Medullary Thyroid Cancer: A Review
2.
Surgery for Tracheoesophageal Fistula: What to Expect Before, During, and After
3.
What Is A Normal Fibrinogen Level, And How Can It Affect Your Health
4.
Breakthroughs in Cancer Care: From Rare Diagnoses to Advanced and Early-Stage Treatments
5.
ERASur: Evaluating Total Ablative Therapy in Limited Metastatic Colorectal Cancer
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer
2.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
3.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI
4.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation